Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells

Merav E Shaul,Asaf Zlotnik,Einat Tidhar,Asaf Schwartz,Ludovica Arpinati,Naomi Kaisar-Iluz,Sojod Mahroum,Inbal Mishalian,Zvi G Fridlender,Merav E. Shaul,Zvi G. Fridlender

DOI: https://doi.org/10.1158/2326-6066.CIR-20-0839

IF: 10.1

2021-07-03

Cancer Immunology Research

Abstract:A major mechanism through which neutrophils have been suggested to modulate tumor progression involves the interaction and subsequent modulation of other infiltrating immune cells. B cells have been found to infiltrate various cancer types and play a role in tumor immunity, offering new immunotherapy opportunities. Nevertheless, the specific impact of tumor-associated neutrophils (TAN) on B cells has largely been overlooked. In the current study, we aimed to characterize the role of TANs in the recruitment and modulation of B cells in the tumor microenvironment (TME). We showed that TANs actively participate in the recruitment of B cells to the TME and identified TNFα as the major cytokine mediating B-cell chemotaxis by TANs. The recruitment of CD45 + B220 + CD138 – splenic B cells by TANs in vitro resulted in B-cell phenotypic modulation, with 68.6% ± 2.1% of the total migrated B cells displaying a CD45 – B220 + CD138 + phenotype, which is typical for plasma cells. This phenotype mirrored the large proportion (54.0% ± 6.1%) of CD45 – B220 + CD138 + intratumoral B cells (i.e., plasma cells) in Lewis lung carcinoma tumors. We next confirmed that the differentiation of CD45 + B220 + CD138 – B cells to functionally active CD45 – B220 + CD138 + plasma cells required contact with TANs, was independent of T cells, and resulted in IgG production. We further identified membranal B-cell activating factor (BAFF) on TANs as a potential contact mechanism mediating B-cell differentiation, as blocking BAFF-receptor (BAFF-R) significantly reduced IgG production by 20%. Our study, therefore, demonstrates that TANs drive the recruitment and modulation of B cells into plasma cells in the TME, hence opening new avenues in the targeting of the immune system in cancer.

oncology,immunology